File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Monoclonal antibody against cadherin-17 as a potential treatment for liver cancer

TitleMonoclonal antibody against cadherin-17 as a potential treatment for liver cancer
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2012
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 47th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress™ 2012), Barcelona, Spain, 18-22 April 2012. In Journal of Hepatology, 2012 , v. 56 suppl. 2, p. S118-S119, abstract no. 287 How to Cite?
AbstractBACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is a major type of liver cancer associated with high mortality. Prognosis is poor in HCC patients largely because of late diagnosis and limitations in treatment options. Therefore, this study aims to identify alternative target for HCC in hope to offer new treatments to patients. Cadherin-17 (CDH17) has been identified as an oncofetal molecule of HCC and that a suppression of its expression by RNA interference (RNAi) leads to anti-tumorigenesis. To supplement the drawbacks associated with the use of RNAi approach in biotherapy, we developed specific antibody against CDH17 for achieving similar purpose. METHODS: Hybridoma cell clones capable of secreting antibodies ...
DescriptionThis journal suppl. entitled: Abstracts of The International Liver Congress™ 2012 – 47th annual meeting of the European Association for the Study of the Liver / Poster Abstracts
Persistent Identifierhttp://hdl.handle.net/10722/165653
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorLee, NP-
dc.contributor.authorWang, Y-
dc.contributor.authorLuk, JM-
dc.date.accessioned2012-09-20T08:21:41Z-
dc.date.available2012-09-20T08:21:41Z-
dc.date.issued2012-
dc.identifier.citationThe 47th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress™ 2012), Barcelona, Spain, 18-22 April 2012. In Journal of Hepatology, 2012 , v. 56 suppl. 2, p. S118-S119, abstract no. 287-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/165653-
dc.descriptionThis journal suppl. entitled: Abstracts of The International Liver Congress™ 2012 – 47th annual meeting of the European Association for the Study of the Liver / Poster Abstracts-
dc.description.abstractBACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is a major type of liver cancer associated with high mortality. Prognosis is poor in HCC patients largely because of late diagnosis and limitations in treatment options. Therefore, this study aims to identify alternative target for HCC in hope to offer new treatments to patients. Cadherin-17 (CDH17) has been identified as an oncofetal molecule of HCC and that a suppression of its expression by RNA interference (RNAi) leads to anti-tumorigenesis. To supplement the drawbacks associated with the use of RNAi approach in biotherapy, we developed specific antibody against CDH17 for achieving similar purpose. METHODS: Hybridoma cell clones capable of secreting antibodies ...-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Hepatology, v. 56, suppl. 2 (April 2012). DOI: 10.1016/S0168-8278(12)60300-6-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleMonoclonal antibody against cadherin-17 as a potential treatment for liver cancer-
dc.typeConference_Paper-
dc.identifier.emailLee, NP: nikkilee@hku.hk-
dc.identifier.emailLuk, JM: jmluk@hku.hk-
dc.identifier.authorityLee, NP=rp00263-
dc.identifier.authorityLuk, JM=rp00349-
dc.description.naturepostprint-
dc.identifier.doi10.1016/S0168-8278(12)60300-6-
dc.identifier.hkuros211326-
dc.identifier.volume56-
dc.identifier.issuesuppl. 2-
dc.identifier.spageS118, abstract no. 287-
dc.identifier.epageS119-
dc.publisher.placeThe Netherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats